Belgium's Argenx Advances On More Positive Efgartigimod Data
Filing Imminent For Promising Myasthenia Gravis Therapy
Executive Summary
Argenx's efgartigimod, an antibody fragment that blocks FcRn, looks most likely to be the first drug to challenge Alexion's Soliris in the myasthenia gravis market after the company presented more positive data from the ADAPT trial.
You may also be interested in...
Launch Of Vyvgart Exceeds Argenx’s Expectations
Tim Van Hauwermeiren, CEO of Argenx, has been on the road with the firm's field force for the US launch of Vyvgart for generalized myasthenia gravis and has been enthused by the positive response from physicians.
UCB Moves Up Myasthenia Gravis Pipeline With Rozanolixizumab Win
Argenx's efgartigimod could very soon become the first anti-FcRn agent to get approval for generalized myasthenia gravis but UCB’s rival therapy rozanolixizumab for the rare muscular disease is nearly ready to be filed with regulators.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.